Maphis said the vaccine was made to combat pathological tau, a protein typically found in a brain with Alzheimer’s.
“These antibodies seem to have cleared pathological tau. Pathological tau is one of the components of these tangles that we find in the brains of patients with Alzheimers disease,” Maphis said.
Related: Promising Alzheimer's vaccine draws closer to human trials, researchers say
According to Maphis, mice with the vaccine performed better in maze-like tests than those without.
The test is not a definitive indicator of the vaccine being the cure. Maphis and Bhaskar are looking or partnerships to test a small group on a clinical grade of the vaccine, KRQE reported. It would cost the department $2 million.